Abeta:
WRT to C3~ uMGMT assuming that is significantly composed of MES, Prins and LL found that MES is more immunogenic than other groups. They did not break down MES into M+/M- groupings. Accordingly, there appears to be a higher level of T-cells in overall MES which are multiplied through the action of the vaccine as well as a less suppressive micro-tumour environment allowing more time for the T-cells to infiltrate the tumour. In less immunogenic groups, it is theorised that a combination of CIs and DC VAX L will "make" the cancer more immunogenic where the CI staves off immune system shutdown in order to allow more time for T-cell infiltration. That is...the micro-tumour environment becomes less immunosuppressive through application of the CI.
WRT MES/M+, I theorise that this group may be susceptible to even longer longevity if not complete remission. In addition to being immunogenic, methylation affects cellular repair mechanisms--damaged cancer cells are not repaired--and so there are at least two "pathways" that extend OS leveraged by the application of adjuvant DC VAX L.
Thus, it would appear that DC VAX L works significantly well in at least three major groupings: M+, M+/MES and M-/MES. In addition, it may have efficacy in the case of EGFr amplification(classical) and whether or not G-cimp status. Dr. Ashkans has been enthusiastic in his support of DC VAX L and as a clinician, he has seen many GBM cases of all stripes. Hence, when he states that the vaccine should be available to all, because it does work, to a greater or lesser degree for these cancers, and that patients are living longer, this is a huge endorsement. I am sure that Dr. Duffy, with his extremely relevant background, is convinced of DC VAX L's efficacy and broad rather than narrow application. Big P is watching and no doubt there are other believers in big P just like Dr. Duffy.
Thanks for your research.
JMHO.
